KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Capital Leases (2020 - 2021)

Historic Capital Leases for Recursion Pharmaceuticals (RXRX) over the last 2 years, with Q4 2021 value amounting to $9.3 million.

  • Recursion Pharmaceuticals' Capital Leases rose 24486.71% to $9.3 million in Q4 2021 from the same period last year, while for Dec 2021 it was $9.3 million, marking a year-over-year increase of 24486.71%. This contributed to the annual value of $9.3 million for FY2021, which is 24486.71% up from last year.
  • Recursion Pharmaceuticals' Capital Leases amounted to $9.3 million in Q4 2021, which was up 24486.71% from $3.5 million recorded in Q3 2021.
  • Recursion Pharmaceuticals' 5-year Capital Leases high stood at $9.3 million for Q4 2021, and its period low was $2.4 million during Q2 2021.